Try a new search

Format these results:

Searched for:

in-biosketch:true

person:tanejs01

Total Results:

831


Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel

Westphalen, Antonio C; McCulloch, Charles E; Anaokar, Jordan M; Arora, Sandeep; Barashi, Nimrod S; Barentsz, Jelle O; Bathala, Tharakeswara K; Bittencourt, Leonardo K; Booker, Michael T; Braxton, Vaughn G; Carroll, Peter R; Casalino, David D; Chang, Silvia D; Coakley, Fergus V; Dhatt, Ravjot; Eberhardt, Steven C; Foster, Bryan R; Froemming, Adam T; Fütterer, Jurgen J; Ganeshan, Dhakshina M; Gertner, Mark R; Mankowski Gettle, Lori; Ghai, Sangeet; Gupta, Rajan T; Hahn, Michael E; Houshyar, Roozbeh; Kim, Candice; Kim, Chan Kyo; Lall, Chandana; Margolis, Daniel J A; McRae, Stephen E; Oto, Aytekin; Parsons, Rosaleen B; Patel, Nayana U; Pinto, Peter A; Polascik, Thomas J; Spilseth, Benjamin; Starcevich, Juliana B; Tammisetti, Varaha S; Taneja, Samir S; Turkbey, Baris; Verma, Sadhna; Ward, John F; Warlick, Christopher A; Weinberger, Andrew R; Yu, Jinxing; Zagoria, Ronald J; Rosenkrantz, Andrew B
Background Prostate MRI is used widely in clinical care for guiding tissue sampling, active surveillance, and staging. The Prostate Imaging Reporting and Data System (PI-RADS) helps provide a standardized probabilistic approach for identifying clinically significant prostate cancer. Despite widespread use, the variability in performance of prostate MRI across practices remains unknown. Purpose To estimate the positive predictive value (PPV) of PI-RADS for the detection of high-grade prostate cancer across imaging centers. Materials and Methods This retrospective cross-sectional study was compliant with the HIPAA. Twenty-six centers with members in the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel submitted data from men with suspected or biopsy-proven untreated prostate cancer. MRI scans were obtained between January 2015 and April 2018. This was followed with targeted biopsy. Only men with at least one MRI lesion assigned a PI-RADS score of 2-5 were included. Outcome was prostate cancer with Gleason score (GS) greater than or equal to 3+4 (International Society of Urological Pathology grade group ≥2). A mixed-model logistic regression with institution and individuals as random effects was used to estimate overall PPVs. The variability of observed PPV of PI-RADS across imaging centers was described by using the median and interquartile range. Results The authors evaluated 3449 men (mean age, 65 years ± 8 [standard deviation]) with 5082 lesions. Biopsy results showed 1698 cancers with GS greater than or equal to 3+4 (International Society of Urological Pathology grade group ≥2) in 2082 men. Across all centers, the estimated PPV was 35% (95% confidence interval [CI]: 27%, 43%) for a PI-RADS score greater than or equal to 3 and 49% (95% CI: 40%, 58%) for a PI-RADS score greater than or equal to 4. The interquartile ranges of PPV at these same PI-RADS score thresholds were 27%-44% and 27%-48%, respectively. Conclusion The positive predictive value of the Prostate Imaging and Reporting Data System was low and varied widely across centers. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Milot in this issue.
PMID: 32315265
ISSN: 1527-1315
CID: 4396982

Re: Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression among Men with Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial

Taneja, Samir S
PMID: 32293960
ISSN: 1527-3792
CID: 4383502

Re: Lifetime Benefits and Harms of PSA-Based Risk Screening for Prostate Cancer

Taneja, Samir S
PMID: 32293966
ISSN: 1527-3792
CID: 4383512

Re: Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)

Taneja, Samir S
PMID: 32293959
ISSN: 1527-3792
CID: 4383492

Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment

Jadvar, Hossein; Ballas, Leslie K; Choyke, Peter L; Fanti, Stefano; Gulley, James L; Herrmann, Ken; Hope, Thomas A; Klitzke, Alan K; Oldan, Jorge D; Pomper, Martin G; Rowe, Steven P; Subramaniam, Rathan M; Taneja, Samir S; Vargas, Herbert Alberto; Ahuja, Sukhjeet
PMID: 32238495
ISSN: 1535-5667
CID: 4370382

Re: Statin Use is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer

Taneja, Samir S
PMID: 32186447
ISSN: 1527-3792
CID: 4352692

Re: 3-Year Freedom from Progression following 68GaPSMA PET CT Triaged Management in Men with Biochemical Recurrence Post Radical Prostatectomy. Results of a Prospective Multi-Center Trial

Taneja, Samir S
PMID: 32186445
ISSN: 1527-3792
CID: 4352682

Reply by Authors

Goldberg, Hanan; Ahmad, Ardalan E; Chandrasekar, Thenappan; Klotz, Laurence; Emberton, Mark; Haider, Masoom A; Taneja, Samir S; Arora, Karan; Fleshner, Neil; Finelli, Antonio; Perlis, Nathan; Tyson, Mark D; Klaassen, Zachary; Wallis, Christopher J D
PMID: 32175794
ISSN: 1527-3792
CID: 4352392

Re: Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study

Taneja, Samir S
PMID: 32073966
ISSN: 1527-3792
CID: 4312322

Re: Long Term Follow-up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (177Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate Cancer

Taneja, Samir S
PMID: 32073970
ISSN: 1527-3792
CID: 4312332